Please login to the form below

Not currently logged in
Email:
Password:

Hutchison MediPharma

This page shows the latest Hutchison MediPharma news and features for those working in and with pharma, biotech and healthcare.

Lilly enters cancer collaboration in China

Lilly enters cancer collaboration in China

Lilly will work with Chi-Med's research-focused subsidiary Hutchison MediPharma to investigate fruquintinib (HMPL-013), a small molecule to inhibit the vascular endothelial growth factor (VEGF) receptor tyrosine kinases. ... Both companies will share

Latest news

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest Intelligence

  • Deal Watch table for October 2013 Deal Watch table for October 2013

    Asset acquisition. Mesenchymal stem cell business, including Prochymal (approved). 100. † Hutchison MediPharma / Eli Lilly.

  • Pharma deals during October 2013 Pharma deals during October 2013

    Focusing on China, Lilly has entered into a licence and co-development agreement with Hutchison MediPharm a for fruquintinib (HMPL-013), a phase II inhibitor of all three forms of Vascular ... Hutchison MediPharma will continue the development of

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Accession

Accession was a born from a passion and a vision. A passion to harness the power of market access to...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics